×
About 10,310 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  2,731 results

Exposure-lag-response associations between weather conditions and ankylosing spondyliti...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314534
BMC Musculoskeletal Disorders; Xin L, Liu J et. al.

Jul 28th, 2021 - Patients with ankylosing spondylitis (AS) have reported that their pain becomes worse when the local weather changes. However, there is limited evidence verifying the short-term associations between meteorological factors and outpatient visits for...

TNF-α inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with an...
https://doi.org/10.1684/ejd.2021.4058
European Journal of Dermatology : EJD; Watabe D, Amano H

Jul 27th, 2021 - TNF-α inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.|2021|Watabe D,Amano H,|

Gastroenterological safety of IL-17 inhibitors: a systematic literature review.
https://doi.org/10.1080/14740338.2021.1960981
Expert Opinion on Drug Safety; Caron B, Jouzeau JY et. al.

Jul 27th, 2021 - Interleukin 17 is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of many chronic immune-mediated disorders. Interleukin 17 inhibitors provide an excellent treatment option for patients with psoriasis, ps...

The combined prevalence of classified rare rheumatic diseases is almost double that of ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296612
Orphanet Journal of Rare Diseases; Leyens J, Bender TTA et. al.

Jul 24th, 2021 - Rare diseases (RDs) affect less than 5/10,000 people in Europe and fewer than 200,000 individuals in the United States. In rheumatology, RDs are heterogeneous and lack systemic classification. Clinical courses involve a variety of diverse symptoms...

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
https://www.ncbi.nlm.nih.gov/pubmed/30717501
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779787
Medicine

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
https://doi.org/10.1136/annrheumdis-2016-210770
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
https://doi.org/10.1136/annrheumdis-2016-209775
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  760 results see all →

Clinicaltrials.gov  133 results

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
https://clinicaltrials.gov/ct2/show/NCT03201445

Apr 16th, 2020 - The primary objective of this study is to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease. Results of this study may be pooled with the results of a separate study being con...

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT03350815

Apr 14th, 2020 - Study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

Clinical Pilates and Aerobic Exercise in Patients With Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT03211559

Apr 13th, 2020 - According to the power analyzes 32 patients, who were diagnosed as Ankylosing spondylitis, will be taken to the study. In the first session their spinal mobility, flexibility, dynamic and static balance, back and lower limb muscle strength, pulmon...

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT03215277

Apr 9th, 2020 - The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).

Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
https://clinicaltrials.gov/ct2/show/NCT00056719

Apr 6th, 2020 - The susceptibility to ankylosing spondylitis (AS) is largely genetically determined. Recent studies suggest that the severity of AS is also influenced by genetic factors. The goal of this study is to identify genes that influence the severity of A...

see more →

News  479 results

Fast Five Quiz: Ankylosing Spondylitis Management
https://reference.medscape.com/viewarticle/932595

May 27th, 2021 - Ankylosing spondylitis (AS) is a recurrent, progressive autoimmune disease that is associated with a high rate of disability. AS is characterized by inflammatory back pain, radiographic sacroiliitis, excess spinal bone formation, and a high preval...

Fast Five Quiz: Ankylosing Spondylitis Management
https://www.medscape.com/viewarticle/932595

May 27th, 2021 - Ankylosing spondylitis (AS) is a recurrent, progressive autoimmune disease that is associated with a high rate of disability. AS is characterized by inflammatory back pain, radiographic sacroiliitis, excess spinal bone formation, and a high preval...

Brodalumab Shows Promise in Axial Spondyloarthritis
https://www.medscape.com/viewarticle/950264

May 3rd, 2021 - NEW YORK (Reuters Health) - Brodalumab may be a potential therapeutic option for patients with axial spondyloarthritis (axSpA), according to interim results of a phase-3 study. Brodalumab, which selectively inhibits interleukin-17 receptor A (IL-1...

Major Advance in the Treatment of Axial Spondyloarthritis Coming
https://www.medscape.com/viewarticle/946520

Feb 26th, 2021 - Rheumatologists can look forward to the likely regulatory approval of the oral Janus kinase inhibitors tofacitinib and upadacitinib for the treatment of axial spondyloarthritis in the first half of 2021, speakers predicted at the 2021 Rheumatology...

Etanercept May Not Help Some With Suspected Nonradiographic Axial Spondyloarthritis
https://www.medscape.com/viewarticle/942849

Dec 17th, 2020 - Treatment with etanercept does not appear to achieve significant clinical improvement in patients suspected of having nonradiographic axial spondyloarthritis (nr-axSpA) but without positive MRI signs of sacroiliitis and/or elevated C-reactive prot...

see more →

Patient Education  10 results see all →